is the only United States company with FDA-approved products containing semaglutide, identified under the trade names Rybelsus, Ozempic and Wegovy
For research uses, common levels range from 0.1 mg/mL to 1.0 mg/mL
A.De JoncheereK.EdejerT.HutubessyR.KienyM
Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026
Determining your individual protein requirement depends on several factors, including your current weight, body composition goals, activity level, and overall health status
Best for adults with BMI 30, or 27 with weight-related conditions, as per FDA guidance
